CSF levels of neurosin (A) and α-synuclein (B) in non-demented controls (CON), Alzheimer's disease patients (AD) and patients with Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies grouped into one cumulative group of patients with synucleinopathy (SYN).

<p>Significant differences in CSF markers, as indicated by the p-values, were evaluated using ANCOVA group comparisons with correction for age or ANOVA followed by Bonferroni posthoc testing.